Safety and efficacy of switching from Aflibercept to Brolucizumab in patients with neovascular AMD

Safety and efficacy of switching from Aflibercept to Brolucizumab in patients with neovascular AMD - Safety and efficacy of switching from Aflibercept to Brolucizumab in patients with neovascular AMD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042729

Enrollment

100

Registered

2020-12-11

Start date

2020-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degenereation

Interventions

Brolucizumab will be intravitreally injected to the eligible eyes with the same injection period of the previous agent, and efficacy and safety of the brolucizumab will be analyzed. The second injecti

t be detected. If the activity of neovascularization reemerges, the injection period will be shortened by 2 weeks until the activity of neovascularization cannot be detected. In case, the injection pe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The eyes with active neovascular age-related macular degeneration under treatment of the existing anti-vascular endothelial grow factor (aflibercept) within 10-week post-injection and need the additional injections within every 8 weeks.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Difference of mean injection period after switching to brolucizumab.	—

Countries

Japan

Contacts

Public ContactTAKAAKI MATSUKI

National Hospital Organization Tokyo Medical Center Ophthalmology

215-rinri@mail.hosp.go.jp03-3411-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026